HOUSTON, Jan. 19, 2021 /PRNewswire/ -- Pharm-Olam, a
global mid-sized clinical research organization (CRO), has been
selected by the U.S. Department of Defense's (DOD) Joint Program
Executive Office for Chemical, Biological, Radiological and Nuclear
Defense (JPEO-CBRND) to lead and provide full service clinical
trial support of the Adalimumab COVID Therapeutic Trial. The
JPEO-CBRND awarded Pharm-Olam a $36.3
million agreement to execute an adaptive, outpatient Phase
II/III clinical trial of the monoclonal antibody, where adalimumab
will be tested as a treatment against the inflammatory response and
associated complications brought on by COVID-19.
Pharm-Olam has been selected by the U.S. Department of Defense as
CRO to support the Adalimumab COVID Therapeutic Trial.
"We are pleased to have been selected by the DOD to conduct this
important clinical trial and support the development of
countermeasures to help those infected by COVID-19," said
Jamie Sischo, Pharm-Olam's Vice
President of Government Programs. "The Adalimumab COVID Therapeutic
Trial will test the safety and efficacy of a treatment for pandemic
sufferers. Further, this agreement expands our dedication and
commitment to slowing and stopping the effects of COVID-19 and adds
to our growing portfolio of federally funded clinical trials,
including support for Operation Warp Speed (OWS)."
"Repurposing an existing FDA-approved drug product for potential
application as a COVID-19 treatment, and possibly as a medical
countermeasure for future biothreats, is an exciting and smart
endeavor that the DOD fully supports," said Dr. Jason Roos, the Joint Program Executive Officer
for Chemical, Biological, Radiological and Nuclear Defense. "This
investment should allow us to save time and lower costs as we
rapidly seek safe and effective treatments to combat this disease,
which is a significant threat to both the warfighter and the
world."
Pharm-Olam has worked with and augmented the efforts of a
variety of government entities, including the Biomedical Advanced
Research and Development Authority (BARDA), part of the HHS Office
of the Assistant Secretary for Preparedness and Response; the
Centers for Disease Control and Prevention (CDC), and National
Institutes of Health (NIH), the DOD and several non-governmental
organizations. Pharm-Olam also holds membership in the Medical CBRN
Defense Consortium and has a strong history of drug development
related to medical countermeasures.
ABOUT PHARM-OLAM LLC
Pharm-Olam is a global clinical research organization that
delivers right-sized trial services to pharmaceutical,
biotechnology, government, and public health organizations around
the world. They specialize in small molecule therapies and
biologics in oncology-hematology, rare disease, allergy,
autoimmune, infectious disease, and vaccines. Founded in 1994, with
operations in 60 countries, this CRO goes the distance to create a
healthier world through agile, innovative, and customized solutions
for Phase I-IV research. Learn how Pharm-Olam helps studies succeed
at www.pharm-olam.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/us-department-of-defense-selects-pharm-olam-as-cro-for-adalimumab-covid-therapeutic-trial-301210354.html
SOURCE Pharm-Olam, LLC